Back to Search
Start Over
The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
- Source :
- BMC Infectious Diseases; 6/12/2020, Vol. 20 Issue 1, p1-11, 11p, 4 Diagrams, 3 Charts
- Publication Year :
- 2020
-
Abstract
- <bold>Background: </bold>Current WHO guidelines (2018) recommend screening for cryptococcal antigen (CrAg) in HIV-infected persons with CD4+ T cell counts< 100 cells/μL, followed by pre-emptive antifungal therapy among CrAg positive (CrAg+) persons, to prevent cryptococcal meningitis related deaths. This strategy may also be considered for those persons with a CD4+ T cell count of < 200 cells/uL according the WHO guidelines. However, there is sparse evidence in the literature supporting CrAg screening and pre-emptive antifungal therapy in those HIV-infected persons with this CD4+ T cell counts< 200 cells/μL.<bold>Method: </bold>We conducted a meta-analysis using data extracted from randomized controlled studies (RCTs) and cohort studies found in a search of Pubmed, Web of Science, the Cochrane Library and the EMBASE/MEDLINE database.<bold>Results: </bold>The pooled prevalence of CrAg positivity in HIV-infected persons with CD4+ T cell counts< 200 cells/μL was 5% (95%CI: 2-7). The incidence of CM in CrAg+ persons was 3% (95%CI: 1-6). Among those CrAg+ persons who did not receive pre-emptive treatment, or those who received placebo, the incidence of CM was 5% (95%CI: 2-9), whereas the incidence of CM among those who received pre-emptive antifungal therapy was 3% (95%CI: 1-6), which is a statistically significant reduction in incidence of 40% (RR: 7.64, 95%CI: 2.96-19.73, p < 0.00001). As for persons with CD4+ T cell counts between 101 ~ 200 cells/μL, the risk ratio for the incidence of CM among those receiving placebo or no intervention was 1.15, compared to those receiving antifungal treatment (95%CI: 0.16-8.13).<bold>Conclusions: </bold>In our meta-analysis the incidence of CM was significantly reduced by pre-emptive antifungal therapy in CrAg+ HIV-infected persons with CD4 <  200 cells/μL. However, more specific observational data in persons with CD4+ T cell counts between 101 ~ 200 cells/μL are required in order to emphasize specific benefit of CrAg screening and pre-emptive antifungal treating in CrAg+ persons with CD4+ T cell counts < 200 cells/μL. [ABSTRACT FROM AUTHOR]
- Subjects :
- HIV-positive persons
T cells
ANTIGENS
CRYPTOCOCCOSIS
COUNTING
MENINGITIS
MENINGITIS prevention
MENINGITIS diagnosis
ANTIFUNGAL agents
META-analysis
SYSTEMATIC reviews
CRYPTOCOCCUS
FUNGAL antigens
DISEASE incidence
MEDICAL screening
CRYPTOCOCCUS neoformans
DISEASE prevalence
CD4 lymphocyte count
RESEARCH funding
AIDS-related opportunistic infections
Subjects
Details
- Language :
- English
- ISSN :
- 14712334
- Volume :
- 20
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- BMC Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 143738087
- Full Text :
- https://doi.org/10.1186/s12879-020-05126-z